Skip Nav Destination
Issues
1 August 2002
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
Editorial
The Biology Behind
Advances in Brief
Clinical Trials
Modulation of the Fas Signaling Pathway by IFN-γ in Therapy of Colon Cancer: Phase I Trial and Correlative Studies of IFN-γ, 5-Fluorouracil, and Leucovorin1
Lee S. Schwartzberg; Istvan Petak; Clinton Stewart; P. Kellie Turner; Jeri Ashley; David M. Tillman; Leslie Douglas; Ming Tan; Catherine Billups; Rudolf Mihalik; Alva Weir; Kurt Tauer; Steve Shope; Janet A. Houghton
Experimental Therapeutics, Preclinical Pharmacology
Regular Articles
Clinical Trials
A Phase I Trial of the Novel Proteasome Inhibitor PS341 in Advanced Solid Tumor Malignancies1
Carol Aghajanian; Steven Soignet; Don S. Dizon; Christine S. Pien; Julian Adams; Peter J. Elliott; Paul Sabbatini; Vincent Miller; Martee L. Hensley; Sandra Pezzulli; Christina Canales; Adil Daud; David R. Spriggs
Administration of a Phorbol Ester to Patients with Hematological Malignancies: Preliminary Results from a Phase I Clinical Trial of 12-O-Tetradecanoylphorbol-13-acetate1
Roger K. Strair; Dale Schaar; Lauri Goodell; Joseph Aisner; Khew-Voon Chin; Joseph Eid; Rachelle Senzon; Xiao Xing Cui; Zheng Tao Han; Beth Knox; Arnold B. Rabson; Richard Chang; Allan Conney
Phase I Trial of the Cryptophycin Analogue LY355703 Administered as an Intravenous Infusion on a Day 1 and 8 Schedule Every 21 Days
James P. Stevenson; Weijing Sun; Maryann Gallagher; Robert Johnson; David Vaughn; Lynn Schuchter; Kenneth Algazy; Stephen Hahn; Nathan Enas; Diane Ellis; Donald Thornton; Peter J. O’Dwyer
A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer1
Anthony W. Tolcher; Leonard Reyno; Peter M. Venner; Scott D. Ernst; Malcolm Moore; Richard S. Geary; Kim Chi; Sean Hall; Wendy Walsh; Andrew Dorr; Elizabeth Eisenhauer
Research Articles
Molecular Oncology, Markers, Clinical Correlates
Normal, Benign, Preneoplastic, and Malignant Prostate Cells Have Distinct Protein Expression Profiles Resolved by Surface Enhanced Laser Desorption/Ionization Mass Spectrometry1
Lisa H. Cazares; Bao-Ling Adam; Michael D. Ward; Suhail Nasim; Paul F. Schellhammer; O. John Semmes; George L. Wright, Jr.
Coexpression of Hypoxia-inducible Factors 1α and 2α, Carbonic Anhydrase IX, and Vascular Endothelial Growth Factor in Nasopharyngeal Carcinoma and Relationship to Survival1
Edwin P. Hui; Anthony T. C. Chan; Francesco Pezzella; Helen Turley; Ka-Fai To; Terence C. W. Poon; Benny Zee; Frankie Mo; Peter M. L. Teo; Dolly P. Huang; Kevin C. Gatter; Philip J. Johnson; Adrian L. Harris
Quantitative Epstein-Barr Virus DNA Analysis and Detection of Gene Promoter Hypermethylation in Nasopharyngeal (NP) Brushing Samples from Patients with NP Carcinoma1
Joanna H. M. Tong; Raymond K. Y. Tsang; Kwok-Wai Lo; John K. S. Woo; Joseph Kwong; Michael W. Y. Chan; Alexander R. Chang; Charles A. van Hasselt; Dolly P. Huang; Ka-Fai To
Genetic Polymorphisms of the Interleukin-4 Receptor α Gene Are Associated with an Increasing Risk and a Poor Prognosis of Sporadic Renal Cell Carcinoma in a Japanese Population1
Eijiro Nakamura; Yuzuru Megumi; Takashi Kobayashi; Toshiyuki Kamoto; Satoshi Ishitoya; Toshiro Terachi; Mitsuhiro Tachibana; Hisanori Matsushiro; Tomonori Habuchi; Yoshiyuki Kakehi; Osamu Ogawa
Experimental Therapeutics, Preclinical Pharmacology
5-aza-2′-Deoxycytidine-induced Expression of Functional Cancer Testis Antigens in Human Renal Cell Carcinoma: Immunotherapeutic Implications1
Sandra Coral; Luca Sigalotti; Maresa Altomonte; Arne Engelsberg; Francesca Colizzi; Ilaria Cattarossi; Eugene Maraskovsky; Elke Jager; Barbara Seliger; Michele Maio
Anti-Vascular Endothelial Growth Factor Receptor 2 Antibody Reduces Tumorigenicity and Metastasis in Orthotopic Prostate Cancer Xenografts via Induction of Endothelial Cell Apoptosis and Reduction of Endothelial Cell Matrix Metalloproteinase Type 9 Production1
Paul Sweeney; Takashi Karashima; Sun-Jin Kim; Daniel Kedar; Badar Mian; Samuel Huang; Cheryl Baker; Zhen Fan; Daniel J. Hicklin; Curtis A. Pettaway; Colin P. N. Dinney
Combretastatin-A4 Prodrug Induces Mitotic Catastrophe in Chronic Lymphocytic Leukemia Cell Line Independent of Caspase Activation and Poly(ADP-ribose) Polymerase Cleavage1
Sanaa M. Nabha; Ramzi M. Mohammad; Mahmoud H. Dandashi; Brigitte Coupaye-Gerard; Amro Aboukameel; George R. Pettit; Ayad M. Al-Katib
Dendritic Cells Genetically Engineered to Simultaneously Express Endogenous Tumor Antigen and Granulocyte Macrophage Colony-stimulating Factor Elicit Potent Therapeutic Antitumor Immunity1
Masaki Nakamura; Makoto Iwahashi; Mikihito Nakamori; Kentaro Ueda; Ichiro Matsuura; Kohei Noguchi; Hiroki Yamaue
Letters to the Editor
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.